General Information of Drug Combination (ID: DCOPY0X)

Drug Combination Name
Vancomycin Ceftriaxone
Indication
Disease Entry Status REF
Nephrolithiasis Phase 4 [1]
Component Drugs Vancomycin   DM3JFIH Ceftriaxone   DMCEW64
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vancomycin
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial endocarditis N.A. Approved [2]
Clostridioides difficile infection 1A04 Approved [2]
Methicillin-resistant staphylococci infection 1A00-1A09 Approved [3]
Neonatal sepsis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
MRSA infection 1D01.0Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Vancomycin Interacts with 14 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
VanA ligase (vanA) DEOFMQ7 Q0WYK7_ENTFL Metabolism [7]
VanA ligase (vanA) DEO97D6 VANA_ENTFC Metabolism [7]
VanB ligase (vanB) DE27YVU Q58F99_ENTFC Metabolism [7]
VanC2 ligase (vanC) DEIF4P9 VANC_ENTGA Metabolism [8]
VanG ligase (vanG) DEPH3S7 A0A076ZC24_STRAP Metabolism [9]
VanA ligase (vanA) DEO8E75 A0A437UFE2_ENTAV Metabolism [7]
VanB ligase (vanB) DER7KFQ VANB_ENTFA Metabolism [7]
VanC2 ligase (vanC) DEH73ZC Q47720_ENTCA Metabolism [10]
D-alanylalanine synthetase (ddl) DE035GU A0A1Q6S944_9FIRM Metabolism [9]
VanG ligase (vanG) DEPN8F9 A0A076YRI6_STRAG Metabolism [9]
VanB ligase (vanB) DEMDEJ8 Q58F99_ENTFC Metabolism [11]
VanB ligase (vanB) DE2GMEK Q58F99_ENTFC Metabolism [11]
VanA ligase (vanA) DEN6VO0 A0A376GZ73_ENTGA Metabolism [12]
VanA ligase (vanA) DESOXHP A0A4U9YK96_ENTCA Metabolism [13], [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DME(s)
Vancomycin Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [14]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [15]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB) OT17HGXJ DMB_HUMAN Affects Expression [14]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [14]
------------------------------------------------------------------------------------
Indication(s) of Ceftriaxone
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [5]
Bacteremia 1A73 Approved [5]
Bacterial arthritis N.A. Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Chancroid N.A. Approved [5]
Endometritis N.A. Approved [5]
Escherichia coli meningitis N.A. Approved [5]
Gonococcal infection of joint N.A. Approved [5]
Meningococcal meningitis N.A. Approved [5]
Pneumococcal meningitis N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Pelvic inflammatory disease GA05 Investigative [5]
Ceftriaxone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Modulator [16]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [17]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [17]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [18]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [19]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEEAL81 BLA2_KLEPO Metabolism [20]
Beta-lactamase (blaB) DEYIEO5 AMPC_SERMA Metabolism [21]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [22]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [23]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02384200) A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
2 Vancomycin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 Ceftriaxone FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
7 Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
8 Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
9 vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
10 Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
11 vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
12 Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
13 vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
14 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
15 [Successful treatment of MRSA-associated glomerulonephritis with antibiotic therapy]. Nihon Jinzo Gakkai Shi. 2003;45(1):37-41.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
18 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
19 Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
20 Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
21 Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
22 Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
23 Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. J Biochem Mol Toxicol. 2015 Mar;29(3):135-9.